current
sever
factor
creat
pressur
improv
deliveri
system
vaccin
first
current
regulatori
environ
grow
requir
develop
vaccin
well
defin
molecular
term
thu
oppos
use
wholeinactiv
pathogen
present
complex
rang
antigen
newli
develop
vaccin
rather
base
select
target
antigen
case
may
singl
molecul
even
fragment
thereof
deriv
infecti
microorgan
tumour
cell
allergen
autoantigen
target
molecul
may
administ
purifi
protein
peptid
may
express
plasmid
dna
recombin
viru
often
molecular
vaccin
poorli
immunogen
impli
need
adjuv
specif
formul
vector
system
enhanc
second
although
past
vaccin
design
stimul
antibodi
respons
surfac
molecul
bacteria
virus
new
gener
vaccin
increasingli
design
elicit
cellular
immun
respons
especi
type
respons
consid
paramount
target
chronic
infecti
diseas
may
intracellular
stage
associ
exampl
herp
virus
hepat
c
viru
helicobact
pylori
plasmodium
falciparum
mycobacterium
tuberculosi
also
develop
therapeut
vaccin
cancer
autoimmun
diseas
new
vaccin
also
develop
elicit
mucos
immun
respons
human
exampl
protect
pathogen
influenza
viru
hsv
human
oncogen
wartassoci
papilloma
virus
unlik
tradit
vaccin
effort
requir
recruit
cellular
mucos
immun
effector
mechan
necessit
explor
new
rout
administr
new
formul
new
adjuv
third
improv
vaccin
administr
gener
either
physician
importantli
custom
toward
painfre
safe
needleless
devic
like
repres
major
driver
futur
vaccin
market
adjuv
encompass
highli
heterogen
group
substanc
capabl
increas
modul
humor
andor
cellular
immun
respons
includ
miner
compound
eg
aluminium
hydroxid
aluminium
phosphat
waterinoil
oilinwat
emuls
eg
incomplet
freund
adjuv
ifa
respect
chemic
genet
detoxifi
bacteri
toxin
cholera
toxin
ct
lymphotoxin
lt
escherichia
coli
saponin
quila
muramyl
di
tripeptid
deriv
mtppe
copolym
iscom
cytokin
cpg
oligonucleotid
combin
thereof
tabl
adjuv
may
facilit
longterm
persist
antigen
inject
site
socal
depot
effect
other
may
target
antigen
present
cell
apc
present
antigen
particul
state
may
specif
elicit
product
pattern
cytokin
relev
induct
effici
enhanc
antibodi
respons
possibl
human
mani
decad
use
aluminium
contrast
enhanc
magnitud
durat
cellular
immun
respons
difficult
achiev
even
lymphoprolif
much
lower
extent
cytotox
tcell
respons
observ
select
antigenadjuv
combin
tabl
elicit
mucos
immun
mani
approach
exploit
solubl
holotoxin
mix
antigen
holotoxin
vibrio
cholera
ct
e
coli
heat
labil
lt
bordetella
pertussi
pt
human
ct
highli
toxic
therefor
attempt
focus
use
ctb
subunit
bind
wide
express
gangliosid
lack
toxic
adpribosyltransferas
activ
associ
subunit
recent
genet
detoxifi
toxin
lack
adp
ribosyltransferas
activ
retain
adjuv
properti
cytokin
gmcsf
accessori
molecul
also
test
immunoadjuv
human
mostli
cancer
patient
mix
result
term
safeti
immunogen
tabl
apart
simpli
admix
antigen
adjuv
formul
strategi
may
aim
facilit
captur
entri
antigen
antigen
present
cell
exampl
formul
tcell
antigen
express
peptid
protein
plasmid
dna
even
rna
cation
liposom
appear
increas
ctl
respons
vivo
anim
liposom
artifici
spheric
close
vesicl
consist
one
lipid
bilay
liposomeencapsul
antigen
deliv
effici
cytoplasm
apc
presum
result
membran
fusion
usual
liposom
made
ester
phospholipid
recent
polar
phospholipid
archebacteria
also
use
lead
socal
archeosom
latter
base
regularli
branch
phytanyl
chain
carbon
length
archeosom
demonstr
better
stabil
high
temperatur
alkalin
ph
serum
protein
compar
convent
liposom
formul
explor
includ
spherulit
multilamellar
vesicl
made
biocompat
amphiphil
transfersom
highli
deform
vesicl
deliv
small
molecul
noninvas
skin
one
liposomebas
approach
proven
success
human
approach
antigen
deriv
hepat
influenza
viru
incorpor
mixtur
natur
synthet
phospholipid
call
virosom
tabl
vaccin
shown
well
toler
induc
seroconvers
rate
high
antibodi
titr
within
exploratori
approach
consist
attach
antigen
small
particl
nonion
block
copolym
synthes
ethylen
oxid
propylen
oxid
produc
vari
surfact
characterist
antigen
formul
base
poli
l
lactid
algin
microspher
appear
anim
model
enhanc
immun
respons
antibodi
tcell
lymphoprolif
mucos
immun
formul
also
facilit
phagocytosi
fluid
phase
intern
antigen
macrophag
dendrit
cell
subsequ
transfer
class
class
ii
present
pathway
increas
effici
compar
solubl
microparticul
antigen
present
system
given
oral
deliv
antigen
mucos
surfac
captur
special
microfold
cell
prior
transfer
peyer
patch
therebi
induc
mucos
addit
inject
microspher
formul
contain
target
antigen
creat
controlledreleas
mechan
allow
possibl
provid
diseas
protect
singl
inocul
absenc
detail
understand
mode
action
develop
adjuv
formul
past
larg
empir
recent
advanc
understand
physiolog
immun
respons
howev
promis
pave
way
ration
design
adjuv
formul
particularli
aim
elicit
immun
notwithstand
potenti
direct
effect
lymphocyt
central
target
adjuvantsformul
apc
theoret
adjuv
formul
futur
follow
properti
collect
recent
insight
proinflammatori
signal
open
way
ration
design
immunoadjuv
particularli
improv
knowledg
biolog
dendrit
cell
antigen
traffick
process
also
provid
clue
design
new
formul
consid
complex
orchestr
seri
event
lead
antigenspecif
activ
immun
system
unlik
singl
molecul
compon
suffic
adjuv
rather
appear
import
combin
variou
molecul
order
achiev
recruit
target
activationcondit
apc
presenc
desir
base
observ
viral
infect
result
present
virusspecif
peptid
associ
mhc
class
mhc
class
ii
surfac
infect
cell
strategi
design
use
virus
immun
vehicl
elicit
antigenspecif
immun
respons
approach
cdna
encod
one
sever
antigen
may
whole
truncat
insert
viral
vector
result
recombin
virus
use
infect
vaccine
aim
caus
express
select
antigen
de
novo
subsequ
present
immun
system
vaccin
purpos
ideal
viral
vector
safe
respect
diseasecaus
potenti
transmiss
longterm
persist
host
enabl
effici
present
express
antigen
immun
system
prefer
exhibit
low
intrins
immunogen
administ
repeatedli
boost
relev
specif
immun
respons
inde
strong
immunogen
adenovir
vector
limit
factor
use
gene
therapi
cancer
well
vaccin
protocol
requir
repeat
administr
immunogen
vector
system
must
also
meet
criteria
enabl
larg
scale
industri
includ
effici
growth
cell
substrat
accept
regulatori
author
total
genet
stabil
respect
attenu
presenc
foreign
gene
scalabl
ten
million
dose
easi
purif
vector
viru
away
cellular
debri
stabil
final
larg
number
rna
dna
virus
develop
experiment
vector
although
flexibl
util
vari
greatli
tabl
sever
base
attenu
viru
strain
use
vaccin
eg
vaccinia
viru
polio
viru
yellow
fever
viru
wherea
other
specif
manipul
minim
diseasecaus
potenti
maxim
immunogen
viral
vector
system
take
advantag
natur
host
restrict
exampl
avipox
virusderiv
vector
replic
avian
cell
unabl
complet
full
round
replic
human
cell
therefor
apathogen
unabl
transmit
persontoperson
howev
capabl
infect
human
cell
express
incorpor
antigen
gene
concept
viral
vector
base
alphavirus
adenoassoci
virus
herp
simplex
virus
engin
remov
critic
gene
requir
gener
complet
infecti
particl
human
vector
requir
helper
system
propag
laboratori
may
vaccin
purpos
advantag
viral
vector
abl
infect
human
apc
dendrit
cell
macrophag
cytopath
viral
vector
still
induc
immun
respons
follow
infect
apc
suggest
cell
retain
capac
initi
immun
respons
least
earli
phase
infecti
cycl
may
apoptot
bodi
contain
antigen
produc
result
viral
infect
captur
uninfect
apc
recent
categori
new
potenti
vector
emerg
base
virallik
particl
vlp
vector
consist
capsid
protein
capabl
selfassembl
noninfecti
viral
particl
heterolog
gene
insert
usual
fusion
protein
capsid
protein
vlp
base
capsid
protein
human
papilloma
virus
hpv
parvoviru
rotaviru
produc
test
success
anim
model
tabl
anoth
potenti
use
viral
vector
vaccin
purpos
accommod
larg
nucleic
acid
insert
base
coronaviru
viru
respons
respiratori
ie
common
cold
also
enter
diseas
human
use
specif
vector
elicit
immun
respons
mucos
surfac
given
howev
virtual
human
develop
antibodi
virus
prior
exposur
interest
coronaviru
vector
human
remain
demonstr
addit
viral
vector
live
bacteria
also
test
carrier
system
dna
vaccin
approach
attenu
mutant
strain
gramposit
gramneg
intracellular
bacteria
use
administ
dna
vaccin
via
mucos
surfac
direct
deliveri
system
target
regard
bcg
listeria
monocytogen
salmonella
typhi
typhimurium
shigella
flexnerii
consid
vector
phagocytos
apc
bacteria
surviv
insid
cell
either
prevent
fusion
phagolysosom
lysosom
exit
phagosom
cytosol
releas
dna
subsequ
enter
nucleu
express
encod
antigen
present
apc
associ
mhc
class
class
ii
molecul
importantli
live
heatinactiv
intracellular
bacteria
also
exhibit
capac
induc
potent
matur
dendrit
cell
therebi
optim
present
heterolog
use
vector
vivo
immun
mice
live
intracellular
bacteria
shown
elicit
humor
cellular
respons
heterolog
bacteri
viral
tumour
antigen
lead
protect
infecti
tumour
challeng
sever
gramneg
bacteria
also
found
deliv
plasmid
dna
human
dendrit
cell
altern
use
whole
bacteria
attempt
made
use
bacteri
protein
lipoprotein
carrier
tcell
aim
outer
membran
protein
eg
ompa
klebsiella
pneumonia
pseudomona
aeruginosa
bacteri
toxin
eg
adenyl
cyclas
toxin
bordetella
pertussi
success
engin
accommod
peptid
repres
heterolog
tcell
bacteri
protein
capac
target
antigen
dendrit
cell
elicit
least
murin
model
strong
ctl
respons
util
bacteri
protein
carrier
capsular
polysaccharid
antigen
also
success
see
articl
finn
elsewher
issu
vaccin
base
plasmid
dna
elicit
strong
antibodi
tcell
respons
anim
model
includ
mice
nonhuman
primat
contrast
use
human
immun
p
falciparum
antigen
vaccin
fail
elicit
antibodi
even
cellular
immun
respons
ctl
detect
use
milligram
quantiti
current
attempt
enhanc
immun
respons
elicit
dna
vaccin
focus
codon
optim
order
enhanc
express
eukaryot
cell
formul
cation
lipid
improv
target
apc
cell
entri
design
dna
vaccin
coexpress
antigen
immunostimulatori
cytokin
approach
given
encourag
result
term
improv
immunogen
anim
model
still
unproven
human
anoth
approach
microscop
particl
coat
plasmid
encod
hepat
b
surfac
antigen
administ
seroneg
human
volunt
skin
use
powderject
particl
acceler
vaccin
well
toler
fail
induc
primari
antibodi
anoth
trend
today
associ
dna
vector
part
mix
primeboost
immun
regimen
associ
exampl
dna
poxvirus
includ
vaccinia
canarypox
alvac
appear
promis
order
induc
antibodi
cellular
respons
anim
test
new
develop
molecular
plant
virolog
includ
exampl
agrobacterium
tumefaciensmedi
gene
transfer
help
gener
plantbas
system
mean
produc
vaccin
antigen
even
immun
antigen
hepat
b
surfac
antigen
e
coli
heatlabil
enterotoxin
rabi
viru
glycoprotein
produc
plantbas
system
shown
elicit
antibodi
includ
system
mucos
iga
fed
oral
mice
human
feed
transgen
lettuc
express
hbsag
transgen
potato
express
e
coli
lt
newcastl
viru
capsid
protein
also
elicit
signific
level
antigenspecif
plant
repres
costeffect
express
system
produc
larg
amount
recombin
protein
express
system
howev
might
suitabl
vaccin
antigen
glycoprotein
addit
vaccin
oral
rout
usual
elicit
strong
system
immun
respons
human
dendrit
cell
dc
current
use
antigen
present
platform
vaccin
cancer
approach
dc
tradit
expand
vitro
monocytederiv
progenitor
subsequ
load
tumourassoci
antigen
form
peptid
protein
recombin
virus
plasmid
dna
rna
formul
cation
lipid
tumour
lysat
dcbase
cellular
vaccin
test
thu
far
human
follow
cancer
target
antigen
bcell
lymphoma
ig
idiotyp
melanoma
tyrosinas
tumour
lysat
bladder
cancer
colorect
cancer
cea
prostat
cancer
psa
pap
collect
vaccin
well
toler
elicit
level
antitumour
ctl
respons
partial
remiss
diseas
stabil
observ
least
fraction
usual
rang
vaccine
despit
encourag
result
procedur
prepar
load
dc
antigen
remain
expens
cumbersom
make
difficult
appli
larg
scale
current
clinic
practic
one
altern
explor
human
consist
isol
exosom
subcellular
organel
contain
mhc
class
ii
tcell
costimulatori
molecul
dc
basi
cellfre
anim
model
exosom
isol
tumour
peptidepuls
dc
could
prime
effici
vivo
cytotox
lymphocyt
capabl
erad
suppress
growth
establish
tumour
number
new
needlefre
modifi
needl
devic
carri
potenti
number
advantag
convent
needl
inject
develop
vaccin
advantag
includ
increas
safeti
accept
therefor
treatment
complianc
well
potenti
increas
efficaci
link
broader
modifi
tissu
distribut
antigen
eas
use
lead
selfadministr
administr
smaller
dose
antigen
adjuv
well
deliveri
via
either
mucos
nasal
oral
subcutan
intraderm
tabl
summar
devic
test
human
macroflux
microneedl
system
allow
administr
antigen
drycoat
onto
microneedl
press
onto
skin
microproject
creat
mechan
pathway
superfici
skin
allow
intracutan
deliveri
antigen
averag
depth
antigen
dose
administ
control
formul
wear
time
system
size
largest
experi
field
needlefre
deliveri
human
gain
varieti
jetinjector
abl
deliv
vaccin
subcutan
devic
use
forc
deriv
two
sourc
power
either
spring
compress
ga
propel
vaccin
skin
needlefre
inject
found
increas
immun
respons
convent
dnabas
vaccin
exampl
seroconvers
rate
well
antibodi
titr
elicit
human
hepat
vaccin
trival
influenza
vaccin
found
increas
least
use
needlefre
inject
oppos
needl
syring
work
requir
howev
control
consist
pressur
inject
ensur
proper
deliveri
vaccin
variou
type
skin
also
greater
depth
administr
greater
discomfort
advantag
springpow
devic
usual
lighter
smaller
gaspow
devic
also
durabl
inexpens
coil
spring
howev
provid
limit
pressur
contrast
gasoper
devic
power
allow
administr
larger
volum
subcutan
intramuscular
rout
ga
cartridg
need
howev
replac
regularli
make
usual
larg
devic
costli
system
oper
coil
spring
system
antigen
administ
either
liquid
form
powder
eg
adsorb
onto
microscop
gold
particl
powderject
system
singledos
injector
also
highspe
multidos
injector
system
allow
mass
immun
develop
recent
transcutan
immun
strategi
introduc
altern
noninvas
administr
approach
antigen
topic
appli
intact
skin
therebi
target
antigen
langerhan
cell
subsequ
migrat
skin
drain
lymph
node
initi
immun
respons
adjuv
usual
associ
antigen
includ
ct
lt
toxin
deriv
v
cholera
e
coli
appli
rehydr
skin
human
volunt
use
patch
vaccin
shown
well
toler
elicit
strong
antibodi
lymphoprolif
respons
antigen
lt
antigen
enterotoxigen
e
coli
lastli
attempt
made
develop
aerosol
deliveri
powder
vaccin
formul
use
advantag
would
includ
eas
use
increas
safeti
dri
powder
formul
would
reduc
refriger
requir
potenti
enhanc
mucos
immun
